
Informa TechTarget Q2 2025: Continuing Momentum, including 15%+ Quarter-over-Quarter Sequential Revenue Growth
Gary Nugent, Chief Executive Officer, Informa TechTarget, said:
'We continue to make good progress through the Foundation Year for Informa TechTarget, delivering sequential improvement in financial performance through Q2, as the impact of our early strategic actions are beginning to bear fruit. We are targeting continuing momentum in H2 as we unlock the benefits of combination in talent, product and go-to-market, and serve our customers with an increasingly powerful portfolio of specialist products and services to help them accelerate their growth.'
Highlights
Q2 Performance Acceleration: Revenues increased 15.5% vs Q1 with encouraging performance in strategic priority areas; Q2 Net Income impacted by technical non-cash impairment reflecting reduction in market capitalization since end of Q1 versus book value;
Continued Progress on Combination Plan: Proceeding at pace during 2025 Foundation Year with focus on reshaping and optimizing the combined company to focus on strengths and capture opportunities from scale, breadth and diversity;
Full Year Guidance Reaffirmed: Improving momentum expected to continue in H2 as combined proposition gains traction; coupled with delivery of cost synergies, this underpins guidance of broadly flat revenues and increase in Adjusted EBITDA to at least $85 million;
Long-term Growth Opportunity: We expect underlying demand for data-driven marketing solutions to remain strong; the scale, breadth and diversity of Informa TechTarget creates a unique opportunity to build a leading position in a long-term growth market;
Financial Summary
2025
2024
2024
Growth
Growth
Six Months Ended June 30
Reported
As Restated
Combined
Reported vs As Restated
$m
$m
$m (1), (2)
%
% (1), (2)
Revenue
$
224
$
122
$
232
84
%
(4
)%
Net loss
$
(922
)
$
(60
)
$
(63
)
n/a
n/a
Net loss margin
(412
)%
(49
)%
(27
)%
n/a
n/a
Adjusted EBITDA (1)
$
23
$
2
$
32
866
%
(27
)%
Adjusted EBITDA margin (%) (1)
10
%
2
%
14
%
8
%
(3
)%
Expand
(1)
Denotes a non-GAAP financial measure. See Non-GAAP Financial Measures below for explanations of these measures and reconciliations to comparable GAAP measures.
(2)
Combined Company measure represents Informa TechTarget's performance for the three and six months ended June 30, 2024 as if the acquisition of Former TechTarget had occurred on January 1, 2023. Note that it is not necessarily indicative of the performance of Informa TechTarget that may have actually occurred had the combination been completed on January 1, 2023.
Expand
Business Performance
We continue to make good progress in combining the complementary strengths of Informa Tech's digital businesses with those of TechTarget, firmly establishing Informa TechTarget with customers in the Foundation Year for the Company.
Our ambition is to become the reference player within data-driven B2B Digital Marketing, a $20 billion growth market, establishing Informa TechTarget as an indispensable source of trusted expertise, knowledge and actionable data, and an essential partner to the B2B technology sector.
Q2 Progress and Momentum
Our focus in Q2 was on further progressing our Combination Plan, whilst continuing to deliver for customers. The market backdrop remained subdued, with enterprise technology customers continuing to limit investments in marketing and sales to prioritize research and development. Despite this, we delivered positive momentum, with the strategic and operational actions already taken beginning to have a positive impact on performance.
We achieved strong sequential growth in Q2 revenues, +15.5% to $120 million, up from the $104 million delivered in Q1. This improving momentum was also reflected year-on-year, with Q2 revenues 1.6% lower than in Q2 2024 on a Combined Company basis, improving from the 5.8% year-on-year decline reported in Q1.
Areas of strength included the NetLine and Industry Dive businesses, which both delivered strong growth through the period. Our paid subscription-based business Omdia, also grew year-on-year, underlining the value of its proprietary data and intelligence offering. The Brand & Intent business remained the most volatile, reflecting the continuing lack of commitment to marketing investment and sales support activities amongst enterprise technology customers, something we are confident will improve over time.
We also continued to expand our strategic partnerships that help customers deliver better outcomes announcing new technology integration partnerships with Demandbase, Outreach and Salesloft.
Q2 adjusted EBITDA was $17.3 million with an adjusted EBITDA margin of 14.4%. This was slightly lower than the prior year period on a Combined Company basis largely as a result of lower year-on-year revenues.
The Company reported a Q2 net loss of $399 million, compared to $31 million for the Combined Company in the prior year period and a narrowing from the net loss in Q1 of $523 million. As previously flagged, the Q2 net loss included a $382 million non-cash impairment, reflecting the reduction in the Company's market capitalization during the quarter relative to book value at the prior quarter-end.
A number of actions supported improving momentum through Q2:
Brand Consolidation: We combined the brands within our Intelligence & Advisory offerings (Canalys, ESG, Omdia and Wards) under the Omdia brand, simplifying the offer to customers and freeing up analysts to spend more time in the field, something reflected in consistent growth through the period;
Focus on Key Accounts: We restructured our go-to-market teams to better target major customer accounts including dedicated sales and service teams with an encouraging growth in bookings from these accounts;
Product Positioning: We made an early decision to reposition the NetLine business, focusing it on the volume end of the demand generation market to distinguish it from other products within our portfolio and target a market segment that is currently experiencing higher levels of activity. This delivered good year-on-year revenue growth in Q2, with continuing growth in bookings into the second half of the year.
Balance Sheet and Liquidity
The Company ended Q2 with a strong balance sheet, including approximately $62 million in cash and cash equivalents, and with $120 million of its $250 million revolving credit facility utilized. This resulted in a net debt position of $58 million, similar to the position at the end of 2024 demonstrating the resilient cash characteristics of the business model.
Compliance with Nasdaq Listing Rules
Following a period of technical delays to filing through the first half of 2025, reflecting the complications of combining a UK IFRS-based subsidiary business with a US GAAP-based small-cap listed business, the Company has now been compliant with filing requirements under Nasdaq Listing Rule 5250(c)(1) for both Q1 and Q2 2025 reporting. With much of the combination activity now behind us, we expect to make future filings in a timely manner, remaining fully compliant with Nasdaq requirements.
The Foundation Year: Re-focusing Resources on Growth
The next phase of our Combination Plan is underway, as detailed in the announcement on July 14, 2025. This sees us refocus our resources more directly into areas of opportunity and growth, enabling us to make the most of our increased scale, breadth and diversity. The plan involves streamlining certain areas and functions while re-investing in others to improve product and service delivery and enhance our go-to-market capabilities. It is expected to lead to a net reduction of approximately 10% of the Company's global colleague base.
As we continue to invest in our capabilities to ensure that we are well-positioned to capture current and future demand, we are also looking forward to an exciting new launch (Informa TechTarget Portal) in the fall that will mark a significant step forward in our product strategy taking the first steps to bring together a unified customer experience and an expansion of our audience data.
Cost synergies
A key output of the Combination Plan is the delivery of $45m in annualized run rate synergies by the end of Year 3 ($25 million of cost synergies and $20 million of profit impact from revenue synergies).
In the Foundation Year, we were originally targeting $5 million of cost synergies. Our accelerated approach to combination and addressing areas of duplication means we now expect to more than double our original Year 1 cost savings goal, delivering a minimum of $10 million operating synergies in 2025 with the majority of these savings to be realized in the second half of the year, putting us firmly on track to deliver our annualized run-rate operating expense savings target.
Audience Development
One of the Company's unique and differentiating factors and a source of long-term value is our proprietary first-party permissioned audience data of over 50 million B2B tech and business professionals worldwide. We serve our audiences by providing trusted market intelligence and analysis that predicts and shapes where technology markets are headed, by producing independent journalism that educates and informs technology and business leaders to help guide their business decisions, and by informing and accelerating the buying journey.
Artificial Intelligence (AI) is evolving the way audiences discover and consume information, including a shift from traditional search to AI-enabled platforms. We have multiple audience engagement strategies that continue to serve us well with active members holding steady. These strategies include Search Engine Optimization (SEO) where our traditional strength translates directly to AI visibility appearing in over 50,000 AI overviews monthly and generating a substantial increase in traffic from AI overviews and with higher conversion rates, but also including the outbound email and newsletter model at Industry Dive which is seeing double-digit growth, partnership models at BrightTALK and NetLine as well as first-party data from Informa PLC. Ultimately, B2B tech buyers require trusted, independent, authoritative sources to support vital technology investment decisions and we continue to prioritize the quality of our 220+ digital brands and were pleased to recently win 45 prestigious online editorial awards across the American Society of Business Publication Editors (ASBPE)'s annual Regional & National Azbee Awards and SIIA's Jesse H. Neal Awards honoring excellence in B2B journalism.
Overall, we continue to see AI as a significant opportunity for us with benefits from it representing a growing customer market to serve, as a tool to utilize for driving efficiencies, and as a technology to power our content generation strategy and value proposition of our products.
2025 Outlook Reaffirmed: Improving momentum into H2
Feedback from our customer engagements and potential pipeline opportunities provide us with confidence that the improving momentum in our business will continue in the second half of the year.
As we continue to execute on our combination plan during this Foundation Year for our business, and as the impact of our strategic actions around our product initiatives and revitalized go-to-market approach continues to build and gain further traction with customers, we anticipate modest sequential improvement in revenues in Q3 that we expect to improve further in Q4 which will also include a boost from the seasonal inclusion of event revenues within our Canalys business.
Overall, we expect the seasonally stronger H2 to deliver year-on-year revenue growth to leave full year 2025 revenues broadly flat compared to 2024 on a Combined Company basis.
The accelerated delivery of cost synergies which we expect will build in the second half of the year and to reach at least $10 million in 2025, including cost savings from the recently-announced reorganization plan, underpins our ambition for positive growth in adjusted EBITDA in 2025 to at least $85 million and an increase in Adjusted EBITDA margin despite broadly flat revenues while also allowing us to invest in our strategic business priorities.
Conference Call and Webcast
The Company will discuss these financial results in a conference call and webcast on Tuesday August 12, 2025 at 8:30 AM (Eastern Time) which will include brief remarks by management followed by questions and answers.
Conference Call Dial-In Information:
United States (Toll Free): 1-833-470-1428
United States: 1-404-975-4839
United Kingdom (Toll Free): +44 808 189 6484
United Kingdom: +44 20 8068 2558
Global Dial-in Numbers
Access code: 967110
Please access the call at least 10 minutes prior to the time the conference is set to begin.
Please ask to be joined into the Informa TechTarget call.
Conference Call Webcast Information:
This webcast can be accessed via Informa TechTarget's website at:
https://investor.informatechtarget.com/
Conference Call Replay Information:
A replay of the conference call will be available via telephone beginning one (1) hour after the conference call through September 11, 2025 at 11:59 p.m. EDT. To hear the replay:
United States (Toll Free): 1-866-813-9403
United States: 1-929-458-6194
Access Code: 703085
About Informa TechTarget
TechTarget, Inc. (Nasdaq: TTGT), which also refers to itself as Informa TechTarget, informs, influences and connects the world's technology buyers and sellers, helping accelerate growth from R&D to ROI.
With a vast reach of over 220 highly targeted technology-specific websites and over 50 million permissioned first-party audience members, Informa TechTarget has a unique understanding of and insight into the technology market.
Underpinned by those audiences and their data, we offer expert-led, data-driven, and digitally enabled services that have the potential to deliver significant impact and measurable outcomes to our clients:
Trusted information that shapes the industry and informs investment
Intelligence and advice that guides and influences strategy
Advertising that grows reputation and establishes thought leadership
Custom content that engages and prompts action
Intent and demand generation that more precisely targets and converts
Informa TechTarget is headquartered in Boston, MA and has offices in 19 global locations. For more information, visit informatechtarget.com and follow us on LinkedIn.
© 2025 TechTarget, Inc. All rights reserved. All trademarks are the property of their respective owners.
Non-GAAP Financial Measures
This release and the accompanying tables include a discussion of Adjusted EBITDA, Adjusted EBITDA Margin, Combined Company Revenue, Combined Company Net Loss, Combined Company Net Loss Margin, Combined Company Adjusted EBITDA, Combined Company Adjusted EBITDA Margin and Net Debt, all of which are non-GAAP financial measures which are provided as a complement to results provided in accordance with GAAP.
'Adjusted EBITDA' means earnings before net interest, income taxes, depreciation and amortization, as further adjusted to exclude stock-based compensation, other income and expenses such as asset impairment and impairment related to goodwill, costs related to mergers, acquisitions or reduction in forces expenses, and foreign exchange gains or losses, if any. As of the second quarter 2025, we have revised our Adjusted EBITDA calculation to exclude the effects of foreign exchange gains and losses, if any, and we have recast comparative prior period amounts accordingly.
'Adjusted EBITDA Margin' means Adjusted EBITDA divided by Revenue.
'Combined Company Revenue' means revenue calculated as if the acquisition of Former TechTarget occurred on January 1, 2023. See Footnote 5 of the Company's Form 10-K for December 31, 2024 for additional information related to our presentation of unaudited supplemental Combined Company financial information.
'Combined Company Net Loss' means net income/loss calculated as if the acquisition of Former TechTarget had occurred on January 1, 2023. See Footnote 5 of the Company's Form 10-K for December 31, 2024 for additional information related to our presentation of unaudited supplemental Combined Company financial information.
'Combined Company Net Loss Margin' means Combined Company Net Loss divided by Combined Company Revenue.
'Combined Company Adjusted EBITDA' means earnings before net interest, income taxes, depreciation and amortization, as further adjusted to exclude stock-based compensation, other income and expenses such as asset impairment and impairment related to goodwill, and costs related to mergers, acquisitions or reduction in forces expenses, if any. See Footnote 5 of the Company's Form 10-K for December 31, 2024 for additional information related to our presentation of unaudited supplemental Combined Company financial information. The items included in the calculation assume the acquisition of Former TechTarget had occurred on January 1, 2023.
'Combined Company Adjusted EBITDA Margin' means Combined Company Adjusted EBITDA divided by Combined Company Revenue.
'Net Debt' at a period end means cash, cash equivalents and short-term investments less financial debt obligations including related party revolving lines of credit.
These non-GAAP measures should be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP results. In addition, our definitions of Adjusted EBITDA, Adjusted EBITDA margin, Combined Company Revenue, Combined Company Net Loss, Combined Company Net Loss Margin, Combined Company Adjusted EBITDA, Combined Company Adjusted EBITDA Margin and Net Debt, may not be comparable to the definitions as reported by other companies. We believe that these measures provide relevant and useful information to enable us and investors to compare our operating performance, and financial position in the case of net debt, using an additional measurement. We use these measures in our internal management reporting and planning process as primary measures to evaluate the operating performance of our business, as well as potential acquisitions.
Combined Company measures are provided to assist our investors in further comparing our performance as if the acquisition of Former TechTarget occurred on January 1, 2023. The components of Adjusted EBITDA and Combined Company Adjusted EBITDA include the key revenue and expense items for which our operating managers are responsible and upon which we evaluate their performance. Adjusted EBITDA is also used in presentations to our Board of Directors. Furthermore, we intend to provide these non-GAAP financial measures as part of our future earnings discussions and, therefore, the inclusion of these non-GAAP financial measures will provide consistency in our financial reporting. A reconciliation of these non-GAAP measures to GAAP is provided in the accompanying tables, except that full reconciliations of certain forward-looking non-GAAP measures are not provided because the Company is unable to provide such reconciliations without unreasonable effort due to the uncertainty and inherent difficulty of predicting the occurrence and financial impact of certain significant items. These items include, but are not limited to, acquisition and integration costs, amortization of intangible assets, restructuring and other expenses, asset impairment, and the income tax effect of these items. These items are uncertain, depend on various factors, including, but not limited to, our recent acquisition of Former TechTarget and could have a material impact on GAAP reported results for the relevant period.
Cautionary Note Regarding Forward-Looking Statements
This press release contains 'forward-looking statements'. All statements, other than historical facts, are forward-looking statements, including: statements regarding the expected benefits of the transactions consummated on December 2, 2024 (the 'Closing Date') pursuant to the Agreement and Plan of Merger, dated as of January 10, 2024, among TechTarget Holdings Inc. (formerly known as TechTarget, Inc. ('Former TechTarget')), Informa TechTarget, Toro Acquisition Sub, LLC, Informa PLC, Informa US Holdings Limited, and Informa Intrepid Holdings Inc. (the 'Transactions'), such as improved operations, enhanced revenues and cash flow, synergies, growth potential, market profile, business plans, expanded portfolio and financial strength; the competitive ability and position of Informa TechTarget; legal, economic, and regulatory conditions; and any assumptions underlying any of the foregoing. Forward-looking statements concern future circumstances and results and other statements that are not historical facts and are sometimes identified by the words 'may,' 'will,' 'should,' 'potential,' 'intend,' 'expect,' 'endeavor,' 'seek,' 'anticipate,' 'estimate,' 'overestimate,' 'underestimate,' 'believe,' 'plan,' 'could,' 'would,' 'project,' 'predict,' 'continue,' 'target,' or the negatives of these words or other similar terms or expressions that concern Informa TechTarget's expectations, strategy, priorities, plans, or intentions. Forward-looking statements are based upon current plans, estimates, and expectations that are subject to risks, uncertainties, and assumptions. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. We can give no assurance that such plans, estimates, or expectations will be achieved, and therefore, actual results may differ materially from any plans, estimates, or expectations in such forward-looking statements.
Important factors that could cause actual results to differ materially from such plans, estimates, or expectations include, among others: unexpected costs, charges, or expenses resulting from the Transactions; uncertainty regarding the expected financial performance of Informa TechTarget; failure to realize the anticipated benefits of the Transactions, including as a result of integrating the Informa Tech Digital Businesses with the business of Former TechTarget; the ability of Informa TechTarget to implement its business strategy; difficulties and delays in Informa TechTarget achieving revenue and cost synergies; evolving legal, regulatory, and tax regimes; changes in economic, financial, political, and regulatory conditions, in the United States and elsewhere, and other factors that contribute to uncertainty and volatility, natural and man-made disasters, civil unrest, pandemics, geopolitical uncertainty, and conditions that may result from legislative, regulatory, trade, and policy changes associated with the current or subsequent U.S. administrations; Informa TechTarget's ability to meet expectations regarding the accounting and tax treatments of the Transactions; market acceptance of Informa TechTarget's products and services; the impact of pandemics and future health epidemics and any related economic downturns on Informa TechTarget and the markets in which it and its customers operate; changes in economic or regulatory conditions or other trends affecting the internet, internet advertising and IT industries; data privacy and artificial intelligence laws, rules, and regulations; the impact of foreign currency exchange rates; certain macroeconomic factors facing the global economy, including instability in the regional banking sector, disruptions in the capital markets, economic sanctions and economic slowdowns or recessions, rising inflation and interest rate fluctuations on the operating results of Informa TechTarget; and other matters included in Risk Factors of Informa TechTarget's Form 10-K for fiscal year 2024 (filed with the United States Securities and Exchange Commission (the 'SEC') on May 28, 2025) and other documents filed by Informa TechTarget from time to time with the SEC. This summary of risks and uncertainties should not be considered to be a complete statement of all potential risks and uncertainties that may affect Informa TechTarget. Other factors may affect the accuracy and reliability of forward-looking statements. We caution you not to place undue reliance on any of these forward-looking statements as they are not guarantees of future performance or outcomes. Actual performance and outcomes, including, without limitation, Informa TechTarget's actual results of operations, financial condition and liquidity, may differ materially from those made in or suggested by the forward-looking statements contained in this press release.
Any forward-looking statements speak only as of the date of this press release. None of Informa TechTarget, its affiliates, advisors or representatives, undertake any obligation to update any forward-looking statements, whether as a result of new information or developments, future events, or otherwise, except as required by law. Readers are cautioned not to place undue reliance on any of these forward-looking statements.
December 31, 2024
Assets
Current assets:
Cash and cash equivalents
$
61,732
$
275,983
Short-term investments
—
77,705
Accounts receivable, net of allowance for credit losses of $1,872 and $907 respectively
78,039
79,039
Related party receivables
6,826
2,900
Prepaid taxes
7,140
6,443
Prepaid expenses and other current assets
14,609
13,547
Total current assets
168,346
455,617
Non-current assets:
Property and equipment, net
3,695
4,621
Goodwill
134,978
973,398
Intangible assets, net
767,896
808,732
Operating lease right-of-use assets
13,696
15,907
Deferred tax assets
5,118
5,097
Other non-current assets
2,790
3,115
Total non-current assets
928,173
1,810,870
Total assets
$
1,096,519
$
2,266,487
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable
$
10,186
$
10,639
Related party payables
18,679
4,795
Contract liabilities
61,504
44,825
Operating lease liabilities
5,240
5,186
Accrued expenses and other current liabilities
22,060
29,328
Accrued compensation expenses
20,923
18,093
Income taxes payable
36,478
6,701
Convertible debt
—
415,690
Total current liabilities
175,070
535,257
Non-current liabilities:
Operating lease liabilities
12,366
15,107
Other liabilities
5,326
4,913
Related party revolving line of credit
120,000
—
Deferred tax liabilities
115,076
139,356
Total non-current liabilities
252,768
159,376
Total liabilities
$
427,838
$
694,633
Stockholders' equity:
Common stock, $0.001 par value; 250,000,000 shares authorized; 71,489,000 shares issued and outstanding at June 30, 2025; 71,460,169 shares issued and outstanding at December 31, 2024
71
71
Additional paid-in capital
1,634,904
1,626,785
Retained deficit
(997,987
)
(75,937
)
Accumulated other comprehensive income
31,693
20,935
Total stockholders' equity
668,681
1,571,854
Total liabilities and stockholders' equity
$
1,096,519
$
2,266,487
Expand
TechTarget, Inc.
Unaudited Condensed Consolidated Statements of Income (Loss) and Comprehensive Income (Loss)
(in thousands, except per share data)
June 30, 2025
June 30, 2024
June 30, 2025
June 30, 2024
As Restated
As Restated
Revenues 1
$
119,943
$
62,968
$
223,830
$
121,627
Cost of revenues 1,2
(51,164
)
(26,701
)
(95,324
)
(50,670
)
Gross profit
68,779
36,267
128,506
70,957
Operating expenses:
Selling and marketing 2
37,063
14,072
70,373
27,879
General and administrative 1,2
18,921
17,394
43,205
35,572
Product development 2
2,596
2,909
5,385
5,928
Depreciation
531
384
1,063
787
Amortization, excluding amortization of $2,950, $143, $5,423 and $245 included in cost of revenues
22,898
11,194
46,186
22,030
Impairment of goodwill
382,248
—
841,348
—
Impairment of long-lived assets
—
155
—
2,019
Acquisition and integration costs 1
14,811
22,477
24,139
29,454
Remeasurement of contingent consideration
—
2,100
—
4,164
Total operating expenses
479,068
70,685
1,031,699
127,833
Operating loss
(410,289
)
(34,418
)
(903,193
)
(56,876
)
Related party interest expense
(2,815
)
(6,202
)
(4,628
)
(12,403
)
Interest income 1
62
1,231
888
2,464
Other income (expense), net
(5,222
)
152
(8,316
)
371
Loss before provision for income taxes
(418,264
)
(39,237
)
(915,249
)
(66,444
)
Income tax benefit (provision)
19,602
(966
)
(6,801
)
6,732
Net loss
$
(398,662
)
$
(40,203
)
$
(922,050
)
$
(59,712
)
Other comprehensive income (loss), net of tax:
Foreign currency translation gain (loss)
6,768
(669
)
10,758
1,882
Total comprehensive loss
$
(391,894
)
$
(40,872
)
$
(911,292
)
$
(57,830
)
Net loss per common share:
Basic
(5.58
)
(0.97
)
(12.90
)
(1.43
)
Diluted
(5.58
)
(0.97
)
(12.90
)
(1.43
)
Weighted average common shares outstanding:
Basic
71,487,725
41,651,366
71,476,670
41,651,366
(1) Amounts include related party transactions as follows:
Revenues
347
70
571
154
Cost of revenues
323
53
600
53
General and administrative
4,917
8,416
10,294
16,921
Interest income
—
834
—
1,863
Acquisition and integration costs
12,101
20,940
19,361
26,995
(2) Amounts include stock-based compensation expense as follows:
Cost of revenues
426
—
734
—
Selling and marketing
2,776
—
5,533
—
General and administrative
773
300
1,484
566
Product development
185
—
368
—
Expand
TechTarget, Inc.
Reconciliation of Net Loss to Adjusted EBITDA and Net Loss Margin to Adjusted EBITDA Margin
($ in thousands)
For Three Months Ended
June 30,
For Six Months Ended
June 30,
2025
2024
2024
2025
2024
2024
As Restated
Combined
As Restated
Combined
Revenues
$
119,943
$
62,968
$
121,882
$
223,830
$
121,627
$
232,177
Net loss
$
(398,662
)
$
(40,203
)
$
(31,108
)
$
(922,050
)
$
(59,712
)
$
(62,696
)
Interest (income) expense, net
2,745
4,972
1,648
3,775
9,939
3,437
Provision (benefit) for income taxes
(19,602
)
966
2,860
6,801
(6,732
)
(3,278
)
Depreciation
531
384
661
1,063
787
1,348
Amortization
25,848
11,337
25,002
51,609
22,275
49,605
EBITDA
$
(389,140
)
$
(22,544
)
$
(937
)
$
(858,802
)
$
(33,443
)
$
(11,584
)
Stock-based compensation
4,160
300
11,643
8,119
566
23,368
Other (income) expense, net
5,230
(152
)
(107
)
8,281
(371
)
(218
)
Impairment of goodwill
382,248
-
-
841,348
-
-
Impairment of long-lived assets
-
155
155
-
2,019
2,019
Acquisition and integration costs
14,811
22,477
6,039
24,139
29,454
13,797
Remeasurement of contingent consideration
-
2,100
2,100
-
4,164
4,164
Adjusted EBITDA
$
17,309
$
2,336
$
18,893
$
23,085
$
2,389
$
31,546
Net loss margin
(332.4
)%
(63.8
)%
(25.5
)%
(411.9
)%
(49.1
)%
(27.0
)%
Adjusted EBITDA margin
14.4
%
3.7
%
15.5
%
10.3
%
2.0
%
13.6
%
Expand
TechTarget Inc.
Reconciliation of Combined Company Revenue and Net Loss
For the three months ended June 30, 2024
($ in thousands)
Historical
Combined Company
Revenues
$
62,968
$
58,914
$
—
$
121,882
Cost of revenues:
Cost of revenues
(26,558
)
(21,414
)
1,274
(c)
(46,698
)
Amortization of acquired technology
(143
)
(703
)
(4,264
)
(d)
(5,110
)
Gross profit
36,267
36,797
(2,990
)
70,074
Operating expenses:
Selling and marketing
14,072
23,187
19
(e)
37,278
General and administrative
17,394
7,625
84
(f)
25,103
Product development
2,909
2,644
—
5,553
Depreciation
384
277
—
661
Amortization
11,194
3,523
5,175
(g)
19,892
Impairment of long-lived assets
155
—
—
155
Acquisition and integration costs
22,477
—
(18,507
)
(h)
3,970
Transaction and related expenses
—
2,069
—
2,069
Remeasurement of contingent consideration
2,100
—
—
2,100
Total operating expenses
70,685
39,325
(13,229
)
96,781
Operating loss
(34,418
)
(2,528
)
10,239
(26,707
)
Interest expense
—
(551
)
—
(551
)
Interest income
1,231
3,874
—
5,105
Other income (expense), net
152
(45
)
—
107
Related party interest expense
(6,202
)
—
—
(6,202
)
Loss before provision for income taxes
(39,237
)
750
10,239
(28,248
)
Income tax benefit (provision)
(966
)
563
(2,457
)
(i)
(2,860
)
Net loss
$
(40,203
)
$
1,313
$
7,782
$
(31,108
)
Expand
(a)
Represents the condensed statement of income of the Informa Tech Digital Business for the quarter ended June 30, 2024.
(b)
Represents the condensed consolidated statement of operations as reported in Former TechTarget's Form 10-Q for the quarter ended June 30, 2024.
(c)
Represents adjustments to cost of revenues associated with the elimination of TechTarget's historical lease expense, amortization related to existing computer software, internal-use software, and website development costs, and the recognition of the estimated lease expense based on remeasured lease liabilities and ROU assets.
(d)
Represents the elimination of Former TechTarget's historical amortization of acquired technology of $703 thousand and recognition of new amortization expense of $4,967 thousand resulting from intangible assets identified as part of the purchase price allocation.
(e)
Represents adjustments to selling and marketing expenses associated with the elimination of Former TechTarget's lease expense, and the recognition of the estimated lease expense based on remeasured lease liabilities and ROU assets.
(f)
Represents adjustments to general and administrative expenses associated with the elimination of Former TechTarget's historical lease expense, and the recognition of the estimated lease expense based on remeasured lease liabilities and ROU assets.
(g)
Represents the elimination of Former TechTarget's historical amortization of intangible assets of $3,523 thousand and recognition of new amortization expense of $8,698 thousand resulting from intangible assets identified as part of the purchase price allocation.
(h)
Represents the elimination of acquisition costs of $18,507 thousand incurred by the Informa Tech Digital Business for the three months ended June 30, 2024.
(i)
Represents the income tax effect of the pro forma adjustments presented. The pro forma income tax adjustments were estimated using a combined U.S. federal and statutory tax rate of 24.0% applied to all adjustments.
Expand
Revenues
$
121,627
$
110,550
$
-
$
232,177
Cost of revenues:
Cost of revenues
(50,425
)
(40,572
)
2,446
(c)
(88,551
)
Amortization of acquired technology
(245
)
(1,405
)
(8,529
)
(d)
(10,179
)
Gross profit
70,957
68,573
(6,083
)
133,447
Operating expenses:
Selling and marketing
27,879
46,149
37
(e)
74,065
General and administrative
35,572
14,320
166
(f)
50,058
Product development
5,928
5,397
—
11,325
Depreciation
787
561
—
1,348
Amortization
22,030
7,048
10,348
(g)
39,426
Impairment of long-lived assets
2,019
—
—
2,019
Acquisition and integration costs
29,454
—
(24,252
)
(h)
5,202
Transaction and related expenses
—
8,595
—
8,595
Remeasurement of contingent consideration
4,164
—
—
4,164
Total operating expenses
127,833
82,070
(13,701
)
196,202
Operating loss
(56,876
)
(13,497
)
7,618
(62,755
)
Interest expense
—
(1,103
)
—
(1,103
)
Interest income
2,465
7,605
—
10,070
Other income (expense), net
371
(153
)
—
218
Related party interest expense
(12,403
)
—
—
(12,403
)
Loss before provision for income taxes
(66,443
)
(7,148
)
7,618
(65,973
)
Income tax benefit (provision)
6,731
(1,627
)
(1,827
)
(i)
3,277
Net loss
$
(59,712
)
$
(8,775
)
$
5,791
$
(62,696
)
Expand
(a)
Represents the condensed statement of income of the Informa Tech Digital Business for the six months ended June 30, 2024.
(b)
Represents the condensed consolidated statement of operations as reported in Former TechTarget's Form 10-Q for the six months ended June 30, 2024.
(c)
Represents adjustments to cost of revenues associated with the elimination of TechTarget's historical lease expense, amortization related to existing computer software, internal-use software, and website development costs, and the recognition of the estimated lease expense based on remeasured lease liabilities and ROU assets.
(d)
Represents the elimination of Former TechTarget's historical amortization of acquired technology of $1,405 thousand and recognition of new amortization expense of $9,934 thousand resulting from intangible assets identified as part of the purchase price allocation.
(e)
Represents adjustments to selling and marketing expenses associated with the elimination of Former TechTarget's lease expense, and the recognition of the estimated lease expense based on remeasured lease liabilities and ROU assets.
(f)
Represents adjustments to general and administrative expenses associated with the elimination of Former TechTarget's historical lease expense, and the recognition of the estimated lease expense based on remeasured lease liabilities and ROU assets.
(g)
Represents the elimination of Former TechTarget's historical amortization of intangible assets of $7,048 thousand and recognition of new amortization expense of $17,396 thousand resulting from intangible assets identified as part of the purchase price allocation.
(h)
Represents the elimination of acquisition costs of $24,252 thousand incurred by the Informa Tech Digital Business for the six months ended June 30, 2024.
(i)
Represents the income tax effect of the pro forma adjustments presented. The pro forma income tax adjustments were estimated using a combined U.S. federal and statutory tax rate of 24.0% applied to all adjustments.
Expand

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a few seconds ago
- Yahoo
Napco, Arlo Technologies, Benchmark, Interface, and TTM Technologies Stocks Trade Up, What You Need To Know
What Happened? A number of stocks jumped in the afternoon session after a key inflation report met expectations, bolstering hopes for a Federal Reserve interest rate cut, while a separate report indicated rising optimism among small businesses. The July Consumer Price Index (CPI) report showed annual inflation holding steady at 2.7%, aligning with forecasts and increasing the probability of a Federal Reserve interest rate cut to over 94%. Lower interest rates can stimulate the economy by making it cheaper for businesses to borrow and invest. Further boosting confidence, the National Federation of Independent Business (NFIB) Small Business Optimism Index rose to a five-month high. This is a crucial indicator for the Business Services sector, as many of its companies cater to small and medium-sized enterprises. The combined positive data fueled a broad, "risk-on" sentiment, where investors favor economically sensitive sectors, leading to gains across IT services, staffing, and manufacturing. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Among others, the following stocks were impacted: Specialized Technology company Napco (NASDAQ:NSSC) jumped 3.4%. Is now the time to buy Napco? Access our full analysis report here, it's free. Specialized Technology company Arlo Technologies (NYSE:ARLO) jumped 5.6%. Is now the time to buy Arlo Technologies? Access our full analysis report here, it's free. Electronic Components & Manufacturing company Benchmark (NYSE:BHE) jumped 4.4%. Is now the time to buy Benchmark? Access our full analysis report here, it's free. Office & Commercial Furniture company Interface (NASDAQ:TILE) jumped 4.7%. Is now the time to buy Interface? Access our full analysis report here, it's free. Electronic Components & Manufacturing company TTM Technologies (NASDAQ:TTMI) jumped 3.9%. Is now the time to buy TTM Technologies? Access our full analysis report here, it's free. Zooming In On Arlo Technologies (ARLO) Arlo Technologies's shares are quite volatile and have had 18 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 4 days ago when the stock gained 10.3% on the news that the company reported stronger-than-expected second-quarter financial results and provided a mostly optimistic outlook. The smart security company posted second-quarter revenue of $129.4 million, beating Wall Street's expectations, while its adjusted earnings of $0.17 per share also surpassed analyst estimates. The quarter highlighted a significant improvement in profitability, with the company's operating margin reaching 1.5%, a substantial increase from negative 9.3% in the same quarter last year. Looking ahead, Arlo projected third-quarter revenue of $138 million at the midpoint, which was above analyst forecasts, although its earnings per share guidance for the upcoming quarter missed expectations. Investors appeared to focus on the strong top-line performance and improved margins, driving the stock higher. Arlo Technologies is up 65.4% since the beginning of the year, and at $18.14 per share, has set a new 52-week high. Investors who bought $1,000 worth of Arlo Technologies's shares 5 years ago would now be looking at an investment worth $3,090. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a few seconds ago
- Yahoo
Stoke Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates
– First patient dosed in the Phase 3 EMPEROR study of zorevunersen in patients with Dravet syndrome – – New 3-year zorevunersen OLE data provide additional support for disease modification: continuing and durable reductions in seizures and improvements in cognition and behavior and generally well tolerated – – Phase 1 study of STK-002 initiated in patients with Autosomal Dominant Optic Atrophy (ADOA), the most common inherited optic nerve disorder – – As of June 30, 2025, the Company had $355.0 million in cash, cash equivalents, and marketable securities, anticipated to fund operations to mid-2028 and into launch readiness – – Webcast and conference call for analysts and investors at 4:30PM Eastern Time today – BEDFORD, Mass., August 12, 2025--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today reported financial results for the second quarter ended June 30, 2025 and provided business updates. "This quarter was defined by strong execution that is driving momentum across our business," said Ian F. Smith, Interim Chief Executive Officer and Director of Stoke Therapeutics. "Our Phase 1/2 and open-label extension studies have provided a strong foundational understanding of zorevunersen and support the EMPEROR Phase 3 registrational study design. We continue to generate long-term data that are helping us appreciate the disease modifying potential of zorevunersen. At the same time, we see growing awareness of Dravet syndrome as a severe neurodevelopmental disease, which is bringing attention to our work and a high degree of interest in zorevunersen." Smith continued, "Beyond Dravet, we have initiated clinical development in a second disease area, advancing STK-002 into a Phase 1 study in patients with Autosomal Dominant Optic Atrophy. Without any treatments approved for ADOA, patients are at risk of progressive loss of sight caused primarily by insufficient OPA1 protein levels. Our pre-clinical data support the potential for STK-002 to restore naturally-occurring protein expression to maintain or improve vision in these patients. We look forward to continuing to expand our approach into new disease areas where we believe we can deliver first-in-class, disease modifying medicines for severe genetic diseases." Recent Program Highlights Yesterday, the Company announced that the first patient has been dosed in the global Phase 3 EMPEROR study of zorevunersen for the treatment of Dravet syndrome. Sites have been initiated in the U.S., UK, Japan and are planned for Europe. Today, the Company announced new positive findings from the long-term open-label extension (OLE) studies of zorevunersen in children and adolescents with Dravet syndrome. Substantial and durable reductions in convulsive seizure frequency on top of standard-of-care medicines were observed through three years of zorevunersen treatment. The data also demonstrate continued improvements in cognition and behavior during the 3-year OLE period beyond the initial 9 months of treatment in the Phase 1/2 studies. Today, the Company announced the Phase 1 study (OSPREY) of STK-002 in patients with Autosomal Dominant Optic Atrophy (ADOA) is now underway. In July, the Company presented data at the European Paediatric Neurology Society (EPNS) Congress from an analysis that evaluated the potential effects on cognition and behavior of a dosing regimen similar to the one now being evaluated in Phase 3. (For full details, see the press release). Upcoming Anticipated Milestones The Company plans to present additional data from the zorevunersen clinical development program at upcoming medical congresses in 2025. Lead optimization is underway to identify a clinical candidate for the treatment of SYNGAP-1 in 2026. SYNGAP-1 is a severe and rare genetic neurodevelopmental disease. Second Quarter 2025 Financial Results As of June 30, 2025, the Company had $355.0 million in cash, cash equivalents, and marketable securities, anticipated to fund operations to mid-2028. Revenue recognized for upfront license fees and services provided from the License and Collaboration Agreement with Acadia Pharmaceuticals for the three months ended June 30, 2025 was $10.6 million, compared to $4.8 million, for the same period in 2024. Revenue recognized from the License and Collaboration Agreement with Biogen for the three months ended June 30, 2025 was $3.2 million. There was no revenue for the same period in 2024. Net loss for the three months ended June 30, 2025 was $23.5 million, or $0.40 per share, compared to a net loss of $25.7 million, or $0.46 per share for the same period in 2024. Research and development expenses for the three months ended June 30, 2025 were $25.9 million, compared to $21.1 million for the same period in 2024. General and administrative expenses for the three months ended June 30, 2025 were $15.3 million, compared to $13.0 million for the same period in 2024. Year-to-Date 2025 Financial Results Revenue recognized for upfront license fees and services provided from the License and Collaboration Agreement with Acadia Pharmaceuticals for the six months ended June 30, 2025 was $16.8 million, compared to $9.0 million for the same period in 2024. Revenue recognized from the License and Collaboration Agreement with Biogen for the six months ended June 30, 2025 was $155.6 million. There was no revenue for the same period in 2024. Net income for the six months ended June 30, 2025 was $89.4 million, or $1.50 per diluted share, compared to a net loss of $52.1 million, or $1.02 per share, for the same period in 2024. Research and development expenses for the six months ended June 30, 2025 were $58.5 million, compared to $43.5 million for the same period in 2024. General and administrative expenses for the six months ended June 30, 2025 were $29.9 million, compared to $23.3 million for the same period in 2024. The increase in operating expenses for the three and six month periods ending June 30, 2025 over the same periods in 2024 primarily relate to increases in costs associated with an increase in personnel and launch readiness expense. Stoke Webcast and Conference Call for Analysts and InvestorsStoke management will host a webcast and conference call for analysts and investors on Tuesday, August 12, 2025, at 4:30pm Eastern Time. The webcast will be available on the Investors & News section of Stoke's website at Research analysts who plan to join the call and participate in the Q&A session may register here to receive the dial-in details and a unique PIN. All other participants are invited to access the listen-only webcast by clicking here. A replay of the webcast will be archived and available for at least 90 days following the event. About Dravet SyndromeDravet syndrome is a severe developmental and epileptic encephalopathy (DEE) characterized by severe, recurrent seizures as well as significant cognitive and behavioral impairments. Most cases of Dravet are caused by mutations in one copy of the SCN1A gene, leading to insufficient levels of NaV1.1 protein in neuronal cells in the brain. More than 90 percent of patients continue to experience seizures despite treatment with the best available anti-seizure medicines. Complications of the disease often contribute to a poor quality of life for patients and their caregivers. Developmental and cognitive impairments often include intellectual disability, developmental delays, movement and balance issues, language and speech disturbances, growth defects, sleep abnormalities, disruptions of the autonomic nervous system and mood disorders. Compared with the general epilepsy population, people living with Dravet syndrome have a higher risk of sudden unexpected death in epilepsy, or SUDEP. Dravet syndrome occurs globally and is not concentrated in a particular geographic area or ethnic group. Currently, it is estimated that up to 38,000 people are living with Dravet syndrome in the U.S. (~16,000), UK, EU-4 and Japan.1 About ZorevunersenZorevunersen is an investigational antisense oligonucleotide that is designed to treat the underlying cause of Dravet syndrome by increasing NaV1.1 protein production in brain cells from the non-mutated (wild-type) copy of the SCN1A gene. This highly differentiated mechanism of action aims to reduce seizure frequency beyond what has been achieved with anti-seizure medicines and to improve neurodevelopment, cognition, and behavior. Zorevunersen has demonstrated the potential for disease modification and has been granted orphan drug designation by the FDA and the EMA. The FDA has also granted zorevunersen rare pediatric disease designation and Breakthrough Therapy Designation for the treatment of Dravet syndrome with a confirmed mutation not associated with gain-of-function, in the SCN1A gene. Stoke has a strategic collaboration with Biogen to develop and commercialize zorevunersen for Dravet syndrome. Under the collaboration, Stoke retains exclusive rights for zorevunersen in the United States, Canada, and Mexico; Biogen receives exclusive rest of world commercialization rights. About Autosomal Dominant Optic Atrophy (ADOA)Autosomal dominant optic atrophy (ADOA) is the most common inherited optic nerve disorder. It is a rare disease that causes progressive and irreversible vision loss in both eyes starting in the first decade of life. Severity can vary and the rate of vision loss can be difficult to predict. Roughly half of people with ADOA fail driving standards and up to 46% are registered as legally blind. More than 400 different OPA1 mutations have been reported in people diagnosed with ADOA. ADOA affects approximately one in 30,000 people globally with a higher incidence in Denmark of one in 10,000 due to a founder effect. Currently there is no approved treatment for people living with ADOA. About STK-002STK-002 is a proprietary antisense oligonucleotide (ASO) in clinical development for the treatment of Autosomal Dominant Optic Atrophy (ADOA). ADOA causes progressive and irreversible vision loss in both eyes starting in the first decade of life. Stoke believes that STK-002 has the potential to be the first disease-modifying therapy for people living with ADOA. An estimated 65% to 90% of cases are caused by mutations in the OPA1 gene, most of which lead to a haploinsufficiency resulting in 50% OPA1 protein expression and disease manifestation. STK-002 is designed to upregulate OPA1 protein expression by leveraging the non-mutant (wild-type) copy of the OPA1 gene to restore OPA1 protein expression with the aim to maintain or improve vision in patients with ADOA. Stoke has generated preclinical data demonstrating proof-of-mechanism and proof-of-concept for STK-002. STK-002 has been granted orphan drug designation by the FDA as a potential new treatment for ADOA. A Phase 1 study (OSPREY) of STK-002 in patients with ADOA is now underway. About Stoke TherapeuticsStoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Using Stoke's proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke's first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study. Stoke's initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for Stoke's proprietary approach. Stoke is headquartered in Bedford, Massachusetts. For more information, visit Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the Company's quarterly results and cash runway; its future operating results and current or future financial position and liquidity; the ability of zorevunersen to treat the underlying causes of Dravet syndrome and reduce seizures or show improvements in behavior and cognition at the indicated dosing levels or at all; the design, timing and results of clinical studies, data readouts, regulatory decisions and other presentations for zorevunersen and STK-002; the ability of STK-002 to treat the underlying causes of Autosomal Dominant Optic Atrophy (ADOA) and maintain or improve vision; our expectations, plans, aspirations and goals, including those related to the potential of zorevunersen and our collaborations with Biogen and Acadia. Statements including words such as "anticipate," "expect," "plan," "will," or "may" and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they prove incorrect or do not fully materialize, could cause the Company's results to differ materially from those expressed or implied by such forward-looking statements, including, but not limited to, risks and uncertainties related to: the Company's ability to advance, obtain regulatory approval and ultimately commercialize its product candidates; that if Biogen were to breach or terminate the collaboration, the Company would not obtain the anticipated financial or other benefits; the possibility that the Company and Biogen may not be successful in their development of zorevunersen and that, even if successful, they may be unable to successfully commercialize zorevunersen; positive results in a clinical trial may not be replicated in subsequent trials or successes in early stage clinical trials may not be predictive of results in later stage trials; the Company's ability to protect its intellectual property; the Company's ability to fund development activities and achieve development goals through mid-2028; and the other risks and uncertainties described under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, its quarterly reports on Form 10-Q, and the other documents it files with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof. Reference: Based on Stoke Therapeutics' preliminary estimates, which scaled annual incidence to prevalence using country-specific live birth rates over the past 85 years and adjusted for Dravet-specific mortality. The estimate is based on incidence rates published by Wu et al., Pediatrics, 2015. Financial Tables Follow Stoke Therapeutics, Inc. and subsidiary Consolidated balance sheets (in thousands, except share and per share amounts) June 30, December 31, 2025 2024 Assets Current assets: Cash and cash equivalents $ 101,472 $ 127,983 Marketable securities - current 146,236 88,916 Prepaid expenses 13,694 11,117 Restricted cash - current 75 75 Interest receivable 1,622 700 Other current assets 6,871 3,965 Total current assets $ 269,970 $ 232,756 Marketable securities - long-term 107,256 29,824 Restricted cash - long-term 721 721 Operating lease right-of-use assets 3,218 4,345 Property and equipment, net 3,343 3,909 Total assets $ 384,508 $ 271,555 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 4,313 $ 2,498 Accrued and other current liabilities 25,616 18,567 Deferred revenue - current portion 8,749 18,991 Total current liabilities $ 38,678 $ 40,056 Deferred revenue - net of current portion 9,632 — Other long term liabilities 1,255 2,478 Total long term liabilities 10,887 2,478 Total liabilities $ 49,565 $ 42,534 Stockholders' equity Common stock, par value of $0.0001 per share; 300,000,000 shares authorized, 54,723,455 and 54,032,826 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively 5 5 Additional paid-in capital 736,276 719,997 Accumulated other comprehensive income (loss) 96 (151 ) Accumulated deficit (401,434 ) (490,830 ) Total stockholders' equity $ 334,943 $ 229,021 Total liabilities and stockholders' equity $ 384,508 $ 271,555 Stoke Therapeutics, Inc. and subsidiary Consolidated statements of operations and comprehensive income (loss) (in thousands, except share and per share amounts) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Revenue $ 13,817 $ 4,831 $ 172,386 $ 9,048 Operating expenses: Research and development 25,855 21,136 58,531 43,504 General and administrative 15,262 13,037 29,915 23,258 Total operating expenses 41,117 34,173 88,446 66,762 Income (loss) from operations (27,300 ) (29,342 ) 83,940 (57,714 ) Other income (expense): Interest income (expense), net 3,789 3,695 6,678 6,121 Other income (expense), net 28 (48 ) 57 (476 ) Total other income (expense) 3,817 3,647 6,735 5,645 Income (loss) before income taxes $ (23,483 ) $ (25,695 ) $ 90,675 $ (52,069 ) Provision for income taxes — — 1,278 — Net income (loss) $ (23,483 ) $ (25,695 ) $ 89,397 $ (52,069 ) Net income (loss) per share: Basic $ (0.40 ) $ (0.46 ) $ 1.54 $ (1.02 ) Diluted (0.40 ) (0.46 ) $ 1.50 (1.02 ) Weighted-average common shares outstanding: Basic 58,353,855 55,765,948 $ 58,109,622 51,288,222 Diluted 58,353,855 55,765,948 $ 59,681,472 51,288,222 Comprehensive income (loss): Net income (loss) $ (23,483 ) $ (25,695 ) $ 89,397 $ (52,069 ) Other comprehensive gain (loss): Unrealized gain (loss) on marketable securities 200 (15 ) 247 9 Total other comprehensive gain (loss) $ 200 $ (15 ) $ 247 $ 9 Comprehensive income (loss) $ (23,283 ) $ (25,710 ) $ 89,644 $ (52,060 ) View source version on Contacts Stoke Media & Investor Contacts: Dawn KalmarChief Communications Officerdkalmar@ 781-303-8302Doug SnowDirector, Communications & Investor RelationsIR@ 508-642-6485 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Yahoo
a few seconds ago
- Yahoo
How major US stock indexes fared Tuesday, 8/12/2025
The U.S. stock market rallied to more records after data suggested inflation across the country was a touch better last month than economists expected. The S&P 500 rose 1.1% Tuesday, beating its all-time high set two weeks ago. The Dow Jones Industrial Average added 1.1%, while the Nasdaq composite climbed 1.4% to its own record. Stocks got a lift from hopes that the better-than-expected inflation report will give the Federal Reserve leeway to cut interest rates at its next meeting in September. Lower rates can give the economy and investment prices a boost. On Tuesday: The S&P 500 rose 72.31 points, or 1.1%, to 6,445.76. The Dow Jones Industrial Average rose 483.52 points, or 1.1%, to 44,458.61. The Nasdaq composite rose 296.50 points, or 1.4%, to 21,681.90. The Russell 2000 index of smaller companies rose 66.27 points, or 3%, to 2,282.78. For the week: The S&P 500 is up 56.31 points, or 0.9%. The Dow is up 283.00 points, or 0.6%. The Nasdaq is up 231.88 points, or 1.1%. The Russell 2000 is up 64.36 points, or 2.9%. For the year: The S&P 500 is up 564.13 points, or 9.6%. The Dow is up 1,914.39 points, or 4.5%. The Nasdaq is up 2,371.11 points, or 12.3%. The Russell 2000 is up 52.62 points, or 2.4%. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data